Review
Biochemistry & Molecular Biology
Ashanti Concepcion Uscanga-Palomeque, Ana Karina Chavez-Escamilla, Cynthia Aracely Alvizo-Baez, Santiago Saavedra-Alonso, Luis Daniel Terrazas-Armendariz, Reyes S. Tamez-Guerra, Cristina Rodriguez-Padilla, Juan Manuel Alcocer-Gonzalez
Summary: This paper reviews the latest developments in CAR-T cells in cancer treatment, including the structure and manufacturing methods of different generations and variants. The challenges and limitations of CAR-T technology in treating hematological and solid cancer are discussed, as well as the use of CAR technology in other immune cells. The paper concludes that CAR-T cells have the potential to treat not only cancer but also other chronic diseases.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Immunology
Haolong Lin, Jiali Cheng, Wei Mu, Jianfeng Zhou, Li Zhu
Summary: CAR-T cell therapy has shown remarkable success in antitumor treatments, particularly against hematological malignancies. The development of universal CAR-T (UCAR-T) cell therapy may overcome current limitations, with a focus on safety, efficiency, and potential complementary immune cells. The landscape and prospects of UCAR-T cell therapy are explored through a comprehensive overview of progress and challenges.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Immunology
Manasi P. Jogalekar, Ramya Lakshmi Rajendran, Fatima Khan, Crismita Dmello, Prakash Gangadaran, Byeong-Cheol Ahn
Summary: CAR-T cell therapy is a promising immune cell therapy for cancer, showing remarkable clinical responses in B-cell leukemia or lymphoma. However, it still faces challenges in treating other hematological and solid tumor malignancies, including severe toxicities and limited anti-tumor efficacy. This review discusses innovative CAR T-cell strategies to improve treatment outcomes and addresses the current challenges and new developments in CAR T-cell therapy.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Sun Il Choi, Jinlong Yin
Summary: Glioblastoma (GBM) is the most common malignant brain tumor, and alternative tumor-specific therapies are urgently needed. Chimeric antigen receptor (CAR) T cell therapy shows promise for hematological malignancies, but its effectiveness for solid tumors, especially GBM, needs improvement. This review discusses strategies for enhancing CAR T cell effectiveness in GBM treatment.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Lusine Hovhannisyan, Carsten Riether, Daniel M. Aebersold, Michaela Medova, Yitzhak Zimmer
Summary: CAR T cell-based therapies have revolutionized the treatment of hematological malignancies. However, the treatment of solid tumors with CAR T cells remains challenging. Radiation therapy, in combination with immune checkpoint inhibitors, has shown promising results in clinical trials. Combining radiation therapy with CAR T cell therapy may overcome the limitations in solid tumor treatment. This review discusses the potential and risks of this combination in cancer patients.
Review
Immunology
Ali Akbar Samadani, Arman Keymoradzdeh, Shima Shams, Armin Soleymanpour, Ali Rashidy-Pour, Houman Hashemian, Sogand Vahidi, Seyedeh Elham Norollahi
Summary: CAR T-cell therapy is a promising immunotherapy for cancer with the potential to treat a variety of solid tumors. By modifying T cells with CAR, it is possible to effectively eliminate certain cancers. Strategies for investigating risks and mitigating off-tumor consequences are crucial, and successful CAR T-cell therapy protocols can enhance the efficacy and safety of treatment.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Review
Medicine, Research & Experimental
Jingtao Zhang, Shuai Liu, Xiubao Chen, Xiangdong Xu, Fei Xu
Summary: Lung cancer is a major cause of cancer-related deaths worldwide. Immunotherapies have revolutionized cancer treatment strategies and have the potential to improve immune responses, response rates, and survival rates. However, a deeper understanding of the complex immunological networks in lung cancer is necessary to enhance the efficacy of immunotherapy.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Review
Clinical Neurology
Kun-Wei Song, Brian J. Scott, Eudocia Q. Lee
Summary: This article outlines the spectrum of neurotoxicity associated with approved immunotherapies and clinical trials. It highlights the advances made in understanding and managing neurotoxicity as the use of cancer immunotherapies becomes more widespread. The expanding indications for immunotherapy have also presented new challenges, such as distinguishing neurotoxicity from disease progression.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS
(2023)
Review
Immunology
Xuechen Yin, Lingfeng He, Zhigang Guo
Summary: Tumour immunotherapy has shown good therapeutic effects in clinical practice and has gained increased attention. Cytotoxic T cells are crucial in this therapy. Chimeric antigen receptor T-cell (CAR-T-cell) therapy, as a revolutionary approach, has made breakthroughs in haematological cancer treatment. However, T-cell exhaustion, especially in solid tumours, hinders the effectiveness of CAR-T-cell therapy. This review discusses the reasons for T-cell exhaustion, its development, and ways to improve CAR-T-cell therapy by regulating T-cell exhaustion.
Review
Medicine, General & Internal
Ella S. Atsavapranee, Margaret M. Billingsley, Michael J. Mitchell
Summary: Genetic engineering has transformed cancer immunotherapy by modifying primary T cells to enhance their therapeutic potential, with studies and clinical trials supporting the effectiveness of this approach.
Review
Immunology
Xiaoling Qin, Fengjiao Wu, Chang Chen, Qi Li
Summary: Colorectal cancer is a common cancer with a serious impact on people's life and health. Although CAR-T cell therapy has shown good efficacy in hematological malignancies, it still faces many challenges in solid tumors such as colorectal cancer. New approaches are being proposed to address these challenges.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biotechnology & Applied Microbiology
Sandy Joaquina, Christopher Forcados, Benjamin Caulier, Else Marit Inderberg, Sebastien Walchli
Summary: Adoptive transfer of CAR T cells has shown success in treating hematological cancers but has faced challenges in treating solid tumors due to the inhibitory effect of the tumor microenvironment. Understanding the metabolic mechanisms in the TME is essential for developing TME-resistant CAR T cells.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
(2023)
Review
Immunology
Fatemeh Nasiri, Mehrasa Kazemi, Seyed Mohamad Javad Mirarefin, Maral Mahboubi Kancha, Milad Ahmadi Najafabadi, Faeze Salem, Setareh Dashti Shokoohi, Sahar Evazi Bakhshi, Pouya Safarzadeh Kozani, Pooria Safarzadeh Kozani
Summary: Triple-negative breast cancer is a complex and difficult-to-treat subtype with limited treatment options. CAR-T therapy shows promise as a potential treatment, but its application in solid tumors, including TNBC, is challenging.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Matthew Bell, Stephen Gottschalk
Summary: CAR T cell therapy is effective for hematological malignancies, but there is a need to improve its efficacy for solid tumors and brain tumors. Several approaches are being pursued to enhance the antitumor activity of CAR T cells, including augmenting signal 3 of T cell activation and improving the function of CAR T cells in the tumor microenvironment.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Immunology
Qiang Feng, Baozhen Sun, Tianyi Xue, Rong Li, Chao Lin, Yongjian Gao, Liqun Sun, Yue Zhuo, Dongxu Wang
Summary: Bile duct, pancreatic, and gastric cancers have limited treatment options and poor prognosis. However, CAR T-cell therapy, a highly effective immunotherapy, can target tumor-associated antigens and effectively inhibit disease progression, improving patient survival.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biochemical Research Methods
Andrea J. Radtke, Colin J. Chu, Ziv Yaniv, Li Yao, James Marr, Rebecca T. Beuschel, Hiroshi Ichise, Anita Gola, Juraj Kabat, Bradley Lowekamp, Emily Speranza, Joshua Croteau, Nishant Thakur, Danny Jonigk, Jeremy L. Davis, Jonathan M. Hernandez, Ronald N. Germain
Summary: IBEX is an iterative immunolabeling and chemical bleaching method that enables highly multiplexed imaging in diverse tissues.
Article
Surgery
Lauren A. Gamble, Alexander Rossi, Grace-Ann Fasaye, Chimene Kesserwan, Jonathan M. Hernandez, Andrew M. Blakely, Jeremy L. Davis
Summary: The study found high rates of occult signet ring cell gastric cancer among carriers of CDH1 P/LP variants with no family history of gastric cancer, suggesting that the germline CDH1 P/LP variants have a highly penetrant gastric phenotype regardless of family history. This data may be useful for counseling families with CDH1 variants presumed to have hereditary lobular breast cancer.
Meeting Abstract
Oncology
Lauren A. Gamble, Martha Teke, Jeremy Fridling, Sarah G. Samaranayake, Bernadette Redd, Andrew Blakely, Jeremy L. Davis
Meeting Abstract
Biochemistry & Molecular Biology
Steven D. Brooks, Xianke Zeng, Mary Jackson, Naomi Tesfuzigta, Kyeisha Laurence, Jessica Nino de Rivera, Jarrett Jackson, Robert Emeh, Rachel Smith, Olena Kamenyeva, Sundar Ganesan, Juraj Kabat, Phillip Cruz, Stacy Joyce, Jeremy Davis, A. Parker Ruhl, Hans Ackerman
Article
Multidisciplinary Sciences
Tahsin M. Khan, Emily A. Verbus, Alexander J. Rossi, Jonathan M. Hernandez, Jeremy L. Davis, Brian A. Coakley, Andrew M. Blakely
Summary: Wild-type KIT and PDGFRA gastrointestinal stromal tumors are rare and have limited treatment options. This study analyzed data from a large national database to identify factors influencing overall survival, finding that tumors in the small intestine and with high mitotic count were associated with decreased OS. Surgery remains the primary treatment modality for wild-type GIST.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Robert R. C. Grant, Tahsin M. Khan, Stephanie N. Gregory, Brian A. Coakley, Jonathan M. Hernandez, Jeremy L. Davis, Andrew M. Blakely
Summary: This study aimed to investigate the potential survival benefit of adjuvant chemotherapy (AC) in patients with stage II colon cancer. The results showed that patients who received AC had significantly increased overall survival (OS) across different numbers of high-risk features. Subgroup analysis revealed a reduced risk of death in patients receiving AC and an increased OS in patients with T4 tumors.
JOURNAL OF SURGICAL ONCOLOGY
(2022)
Article
Genetics & Heredity
Benjamin L. Green, Grace-Ann Fasaye, Sarah G. Samaranayake, Anna Duemler, Lauren A. Gamble, Jeremy L. Davis
Summary: Pathogenic and likely pathogenic variants in the CDH1 gene are associated with increased risk of gastric and breast cancers, as well as hereditary cleft lip and palate (CLP). This study aimed to determine the prevalence of CLP in families with these variants. The results showed a high prevalence of CLP in families carrying CDH1 variants, with no clear genotype-phenotype pattern. Genetic testing for CDH1 should be considered in families with CLP and a history of gastric or lobular breast cancer.
FRONTIERS IN GENETICS
(2022)
Article
Oncology
Benjamin L. Green, Alisa N. Blumenthaler, Lauren A. Gamble, James D. McDonald, Kristen Robinson, Maureen Connolly, Monica Epstein, Jonathan M. Hernandez, Andrew M. Blakely, Brian D. Badgwell, Jeremy L. Davis
Summary: CRS-HIPEC treatment for gastric adenocarcinoma with peritoneal metastasis showed a 3-year survival rate of 22% and common complications. The number of lymph node metastases was inversely correlated with overall survival.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Editorial Material
Oncology
Benjamin L. Green, Alisa N. Blumenthaler, Lauren A. Gamble, James D. McDonald, Kristen Robinson, Maureen Connolly, Monica Epstein, Jonathan M. Hernandez, Andrew M. Blakely, Brian D. Badgwell, Jeremy L. Davis
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Genetics & Heredity
Xi Luo, Jamie L. Maciaszek, Bryony A. Thompson, Huei San Leong, Katherine Dixon, Sonia Sousa, Michael Anderson, Maegan E. Roberts, Kristy Lee, Amanda B. Spurdle, Arjen R. Mensenkamp, Terra Brannan, Carolina Pardo, Liying Zhang, Tina Pesaran, Sainan Wei, Grace-Ann Fasaye, Chimene Kesserwan, Brian H. Shirts, Jeremy L. Davis, Carla Oliveira, Sharon E. Plon, Kasmintan A. Schrader, Rachid Karam
Summary: Germline pathogenic variants in CDH1 are associated with increased risk of diffuse gastric cancer and lobular breast cancer. Accurate interpretation of these variants is critical for physicians deciding on risk reduction strategies, such as prophylactic surgery. The development of CDH1-specific interpretation guidelines by experts has led to improved clinical management recommendations.
JOURNAL OF MEDICAL GENETICS
(2023)
Article
Endocrinology & Metabolism
Lauren A. Gamble, Rachael Lopez, Suraj Rajasimhan, Sarah G. Samaranayake, Cassidy Bowden, Amber L. Famiglietti, Andrew M. Blakely, Smita Jha, Mark A. Ahlman, Jeremy L. Davis
Summary: Patients with CDH1 germline variants undergoing prophylactic TG are at risk of bone mineral density loss and micronutrient deficiencies. Serum biomarkers of mineral metabolism did not change significantly, but average BMD was decreased at 12 months post-TG. Adherence to calcium and multivitamin supplementation is associated with the preservation of BMD.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Review
Oncology
Stephanie N. Gregory, Jeremy L. Davis
Summary: Hereditary diffuse gastric cancer (HDGC) is an autosomal dominant cancer syndrome associated with a high risk of diffuse-type gastric cancer. Loss-of-function mutations in the CDH1 gene have been identified as the primary cause of HDGC. Prophylactic total gastrectomy (PTG) is recommended, but surveillance may also be an alternative for selected patients.
CHINESE CLINICAL ONCOLOGY
(2023)
Article
Oncology
Bilal Asif, Amber Leila Sarvestani, Lauren A. Gamble, Sarah G. Samaranayake, Amber L. Famiglietti, Grace -Ann Fasaye, Martha Quezado, Markku Miettinen, Louis Korman, Christopher Koh, Theo Heller, Jeremy L. Davis
Summary: This study aimed to evaluate the safety and effectiveness of endoscopy in individuals with CDH1 variants, particularly in those who declined prophylactic total gastrectomy. The study found that endoscopy had a certain level of safety and effectiveness in early detection and interception of gastric cancer.
Article
Oncology
Benjamin L. Green, Alisa N. Blumenthaler, Lauren A. Gamble, James D. McDonald, Kristen Robinson, Maureen Connolly, Monica Epstein, Jonathan M. Hernandez, Andrew M. Blakely, Brian D. Badgwell, Jeremy L. Davis
Summary: In patients with gastric adenocarcinoma and isolated peritoneal metastasis treated with CRS-HIPEC, the 3-year overall survival rate from CRS-HIPEC was 22%, and complications were common. The number of pathologic lymph node metastases was inversely correlated with overall survival.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Meeting Abstract
Oncology
Areeba Saif, Amber Leila Sarvestani, Carrie Ryan, Kirsten Remmert, Stephanie Lux, Martha Teke, Emily Verbus, Tahsin M. Khan, Jacob Lambdin, Allen Luna, Surajit Sinha, Andrew Blakely, Jeremy Davis, Jonathan Hernandez
ANNALS OF SURGICAL ONCOLOGY
(2022)